DexCom (DXCM) Tops Q4 EPS by 7c; offers guidance
Tweet
Share
E-mailGet Alerts DXCM Hot Sheet
Price: $89.24 +1.49%
EPS Growth %: +9.8%
Financial Fact:
Operating loss: -18.5M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: +9.8%
Financial Fact:
Operating loss: -18.5M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
(Updated - February 8, 2024 4:46 PM EST)
DexCom (NASDAQ: DXCM) reported Q4 EPS of $0.50, $0.07 better than the analyst estimate of $0.43. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $1.02 billion.
GUIDANCE:
DexCom sees FY2024 revenue of $4.15-4.35 billion, versus the consensus of $4.33 billion.
For earnings history and earnings-related data on DexCom (DXCM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2
- Lumentum shares rise on analyst upgrades, AI demand outlook
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
